Health Care & Life Sciences » Pharmaceuticals | Pacira Pharmaceuticals Inc.

Pacira Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
85,551.00
197,668.00
248,997.00
276,371.00
286,630.00
337,277
Cost of Goods Sold (COGS) incl. D&A
54,772.00
77,440.00
71,837.00
110,104.00
87,915.00
86,845
Gross Income
30,779.00
120,228.00
177,160.00
166,267.00
198,715.00
250,432
SG&A Expense
84,068.00
125,393.00
167,705.00
191,191.00
211,684.00
225,853
EBIT
53,289.00
5,165.00
-
24,924.00
12,969.00
24,579
Unusual Expense
3,398.00
-
52.00
7,100.00
15,700.00
8,664
Non Operating Income/Expense
47.00
159.00
165.00
82.00
167.00
888
Interest Expense
7,876.00
8,601.00
7,796.00
7,061.00
18,047.00
21,949
Pretax Income
64,351.00
13,543.00
2,120.00
37,844.00
42,471.00
425
Income Tax
442.00
173.00
264.00
105.00
140.00
46
Consolidated Net Income
63,909.00
13,716.00
1,856.00
37,949.00
42,611.00
471
Net Income
63,909.00
13,716.00
1,856.00
37,949.00
42,611.00
471
Net Income After Extraordinaries
63,909.00
13,716.00
1,856.00
37,949.00
42,611.00
471
Net Income Available to Common
63,909.00
13,716.00
1,856.00
37,949.00
42,611.00
471
EPS (Basic)
1.93
0.39
0.04
1.02
1.07
0.01
Basic Shares Outstanding
33,181.90
35,299.00
36,540.00
37,236.00
39,806.00
40,911
EPS (Diluted)
1.93
0.39
0.04
1.02
1.07
0.01
Diluted Shares Outstanding
33,181.90
35,299.00
41,301.00
37,236.00
39,806.00
40,911
EBITDA
47,542.00
4,870.00
20,930.00
12,005.00
864.00
37,744
Non-Operating Interest Income
259.00
382.00
678.00
1,323.00
4,078.00
6,497

About Pacira Pharmaceuticals

View Profile
Address
5 Sylvan Way
Parsippany New Jersey 07054
United States
Employees -
Website http://www.pacira.com
Updated 07/08/2019
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.